Figure 2
Figure 2. rTf-activated CTI-inhibited blood with or without EA.hy926 cells. Bare tubes (■) and tubes containing a unilaminar layer of EA.hy926 (○) were used to measure (A) TAT formation over time after CTI-inhibited fresh blood activation with 5 pM rTf, (B) FPA production, (C) normalized fibrinogen consumption with a representative Western blot of a single subject and (D) fVa generation (left) and inactivation (right) as quantified by densitometry of Western blot analysis using α-fV no. 17 HC antibody showing fVa HC and fVa307-506 HC cleavage product (bottom). FVa1-506 HC cleavage is also shown but was not quantified. Clot times in all experiments are indicated (■ = 3.0 ± 0.17 minutes and ○ = 2.9 ± 0.14 minutes). Dashed line in a and b represents 95% confidence limits.

rTf-activated CTI-inhibited blood with or without EA.hy926 cells. Bare tubes (■) and tubes containing a unilaminar layer of EA.hy926 (○) were used to measure (A) TAT formation over time after CTI-inhibited fresh blood activation with 5 pM rTf, (B) FPA production, (C) normalized fibrinogen consumption with a representative Western blot of a single subject and (D) fVa generation (left) and inactivation (right) as quantified by densitometry of Western blot analysis using α-fV no. 17 HC antibody showing fVa HC and fVa307-506 HC cleavage product (bottom). FVa1-506 HC cleavage is also shown but was not quantified. Clot times in all experiments are indicated (■ = 3.0 ± 0.17 minutes and ○ = 2.9 ± 0.14 minutes). Dashed line in a and b represents 95% confidence limits.

Close Modal

or Create an Account

Close Modal
Close Modal